H.R. 10549, Patient Choice and Pharmacy Competition Protection. Quorum's AI analysis reads it as a net benefit — and names who gains.
H.R. 10549 · Net good
What it does
This bill prohibits health insurance plans and insurers from steering patients toward pharmacies they own or control when filling specialty drug prescriptions. It bars plans from charging higher copays for non-affiliated pharmacies, offering financial incentives to use affiliated ones, or creating administrative delays for independent pharmacies. Plans must accept any licensed, qualified specialty pharmacy willing to meet uniform network terms and accept standard reimbursement rates, with narrow exceptions for fraud, Medicare exclusion, or documented patient-safety risk.
The analysis names independent specialty pharmacies — and 2 more groups — among the beneficiaries.
The trade-off
Effective date of January 1, 2029 delays implementation by ~3 years, giving insurers and PBMs time to restructure affiliated pharmacy arrangements or divest holdings before the rule takes effect.
Transparency scores 85%, with a medium warning level and no provisions unrelated to the bill's subject.
Who is behind it
Filed by Neal Dunn. Cosponsored by Joe Wilson.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.